Bevacizumab in the First-line Treatment of advanced Ovarian Cancer

被引：0
|
作者：
Mallmann, Michael R. [1 ]
Alakus, Hakan [2 ]
Mallmann, Peter [1 ]
Bruns, Christiane [2 ]
机构：
[1] Univ Klinikum Koln AoR, Klin & Poliklin Geburtshilfe & Frauenheilkunde, Kerpener Str 34, D-50937 Cologne, Germany
[2] Univ Klinikum Koln AoR, Klin & Poliklin Allgemein Viszeral & Tumorchirurg, Cologne, Germany
来源：
ONKOLOGE | 2019年 / 25卷 / 11期
关键词：
D O I：
10.1007/s00761-019-00659-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1020 / 1021
页数：2
相关论文
共 50 条
  • [1] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [2] Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
    Conic, Irena
    Nedovic, Bojan
    Stojnev, Slavica
    Todorovska, Ilinka
    Dimitrijevic, Aleksandra
    Krstic, Miljan
    Djordjevic, Ivana
    Djordjevic, Biljana
    [J]. MEDICINA-LITHUANIA, 2022, 58 (05):
  • [3] Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy
    Lee, Jung-Yun
    Kim, Kyunghoon
    Lee, Yun Shin
    Kim, Hyo Young
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Jae Weon
    Kim, Young Tae
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 622 - 627
  • [4] NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer
    Dyer, Matthew
    Richardson, Joanna
    Robertson, Janet
    Adam, Jane
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 689 - 690
  • [5] Bevacizumab in der Erstlinientherapie des fortgeschrittenen OvarialkarzinomsBevacizumab in the first-line treatment of advanced ovarian cancer
    Michael R. Mallmann
    Hakan Alakus
    Peter Mallmann
    Christiane Bruns
    [J]. Der Onkologe, 2019, 25 (11): : 1020 - 1021
  • [6] SLOVENIAN EXPERIENCE WITH BEVACIZUMAB IN FIRST-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Gregoric, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A53 - A54
  • [7] Bevacizumab combined with a taxane and a platinum agent as first-line treatment for advanced-stage ovarian cancer
    Kato, Kazuyoshi
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 30 - 30
  • [8] First-Line Therapy with Bevacizumab - Standard in advanced Ovarian Carcinoma
    Pohlmann, Birgit-Kristin
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 382 - 383
  • [9] Bevacizumab as first-line therapy for advanced breast cancer
    Bartsch, R.
    de Vries, C.
    Foedermayr, M.
    Mader, R. M.
    Huber, M.
    Bago-Horvath, Z.
    Pluschnig, U.
    Steger, G. G.
    Dubsky, P.
    Fitzal, F.
    Schreil, G.
    Zielinski, C. C.
    Gampenrieder, S. P.
    Ziebermayr, R.
    [J]. ONKOLOGIE, 2010, 33 : 16 - 16
  • [10] Bevacizumab Combination TherapyFor the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    Sohita Dhillon
    [J]. Drugs, 2012, 72 : 917 - 930
12345